Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Pancreatic Neoplasms 2Ovarian Neoplasms 2Neoplasm Metastasis 2Melanoma 2Lung Neoplasms 2Breast Neoplasms 2Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma 1Prostatic Neoplasms 1Neoplasms 1Liver Neoplasms 1Leukemia 1Kidney Neoplasms 1Glioblastoma 1Esophageal Neoplasms 1Disease 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Bronchogenic 1

Interventions

pembrolizumab 4Magnetic Resonance Spectroscopy 4trametinib 3selpercatinib 3Trastuzumab 3ulixertinib 2larotrectinib 2binimetinib 2belinostat 2alectinib 2Sunitinib 2Specimen Handling 2Radiotherapy 2Paclitaxel 2Nivolumab 2Fluorouracil 2Fluorodeoxyglucose F18 2Cyclophosphamide 2Cisplatin 2Cetuximab 2Biopsy 2130-nm albumin-bound paclitaxel 2vandetanib 1trastuzumab deruxtecan 1trastuzumab biosimilar HLX02 1tislelizumab 1tipifarnib 1spartalizumab 1sargramostim 1sapanisertib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Thyroid Neoplasms × Interleukin-15 × Thoracic × Clear all
NCT03127098 2024-08-06

QUILT-3.040: ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing Cancer

NantCell, Inc.

Phase 1/2 Terminated
3 enrolled 6 charts
BreastGastrointestinalGynecologicHead & NeckThoracic

Breast Neoplasms, Colonic Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Thyroid Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡